Sermorelin vs Ipamorelin vs Tesamorelin: What the Data Says About Quality Variance

People compare Sermorelin, Ipamorelin, and Tesamorelin as if the only question is "which one is better." In practice, the first question is more basic:

What do lab results show about what is actually in the vial?

Vendor pages often use selective COAs to support claims. A more useful view comes from repeated testing across many samples and many vendors. Finnrick test results make it possible to compare real-world variance in purity and quantity for each compound, and to see how often label claims match measured results.

This article lays out what testing can verify, what it cannot, and what Finnrick test data shows for these three peptides.

TL;DR

• What can testing verify? Identity (method-dependent), purity (within the method), and quantity versus label claim or batch claim.
• What can't testing verify? What you "should do," who manufactured a sample (in many cases), or whether one COA predicts future batches.
• What does the data suggest? Quantity variance is often the bigger issue than purity. The dataset shows meaningful differences in typical quantity divergence across these compounds.

What a COA Can Verify (and What It Cannot)

A Certificate of Analysis (COA) reports measurements for a specific sample. In this context, there are three practical questions a COA may help answer:

• Identity: Does the sample contain the compound claimed on the label?
• Purity: How much of the measured signal corresponds to the intended compound versus other detectable peptide-like material under the method?
• Quantity (potency): How does the measured amount compare to the claim?

A COA does not automatically answer:

• whether the sample is representative of what other buyers receive from the same vendor,
• whether future batches will match,
• or whether the sample origin is what the label implies (especially when batch identifiers are missing).

The best use of a COA is as one data point in a broader pattern: repeated testing, consistent labeling, and stable results over time.

What Finnrick Test Results Show

Sermorelin: Fewer Tests, Tighter Quantity Range (Relative)

Finnrick has tested 23 Sermorelin samples from 5 vendors (20 Apr 2025 to 13 May 2026). Purity typically ranges from 96.58% to 99.95% (5th–95th percentile). Quantity typically diverges by up to ±50% versus advertised value (95th percentile).

Interpretation: In this dataset, the quantity divergence band is meaningful, but it is narrower than what appears on Tesamorelin and comparable pages. That does not mean any single vial is predictable. It means the observed spread across tested samples is smaller at the high end of the distribution.

Ipamorelin: High Sample Volume, Quantity Divergence Still Large

Finnrick has tested 284 Ipamorelin samples from 51 vendors (13 Feb 2025 to 20 May 2026). Purity typically ranges from 97.00% to 99.96% (5th–95th percentile). Quantity typically diverges by up to ±69% versus advertised value (95th percentile).

Interpretation: Purity is typically high, but quantity variance is still large enough to matter. This is a good example of why "purity looks fine" is not the same as "label claims are accurate."

Tesamorelin: Large Sample Volume, Very Wide Quantity Divergence

Finnrick has tested 404 Tesamorelin samples from 45 vendors (7 May 2025 to 20 May 2026). Purity typically ranges from 78.31% to 99.95% (5th–95th percentile). Quantity typically diverges by up to ±100% versus advertised value (95th percentile).

Interpretation: This is a wider purity range than Sermorelin and Ipamorelin, and the quantity divergence band is also wider. A ±100% 95th-percentile divergence implies that outliers can be extreme and that "trust the label" is not a safe default assumption.

What to Watch for When Comparing Vendors (Verification-First)

If the goal is to choose a vendor based on evidence instead of marketing, the biggest mistake is providing significant weight to a single COA screenshot. A stronger approach looks for repeatable signals.

A) Batch Identifiers: The Difference Between "A Test Result" and "A Predictor"

Without a batch identifier, a test result is less useful for predicting what someone else will receive. A batch ID lets you compare like-with-like.

Practical rule: If there is no batch ID, treat results as descriptive, not predictive.

B) Quantity vs Purity: Don't Treat Them as Interchangeable

Purity and quantity measure different things. A sample can test high on purity and still diverge meaningfully from the label claim on quantity.

Practical rule: When purity is high, check quantity next. Quantity mismatch is often the more actionable discrepancy.

C) Consistency Over Time Beats a Single "Perfect" Result

One clean test can happen by chance. Consistency across multiple tests and across time is harder to fake and more useful as a trust signal.

Practical rule: Prefer vendors with repeatable results across several tests, not vendors with one impressive COA.

Common Questions

Which matters more in testing: purity or quantity?

Both matter, but the dataset often shows that quantity divergence is the larger real-world mismatch versus what the label claims, even when purity is high.

Can testing tell you what you should do?

No. Testing is not advice. It provides measurement: what is present, how pure it is under the method, and how quantity compares to a claim.

Does a COA prove a vendor is trustworthy?

A COA can be informative, but trust is better built through repeatable patterns: consistent results, batch-level traceability, and transparent reporting.

Takeaway

Sermorelin, Ipamorelin, and Tesamorelin are often compared as products. The more defensible comparison starts with verification.

Finnrick test results show:

• All three compounds can present meaningful variance in measured quantity versus label claims.
• Tesamorelin shows a much wider quantity divergence band (95th percentile) than Sermorelin and Ipamorelin in the available dataset.
• Purity can look "fine" while quantity still diverges enough to matter.

If you want to replace speculation with evidence for a specific vial, submitting a sample for testing is the most direct step.